Nailloux, France

Philippe Schmitt

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Philippe Schmitt: Innovator in Cancer Treatment

Introduction

Philippe Schmitt is a notable inventor based in Nailloux, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of four patents to his name, Schmitt's work is recognized for its potential impact on medical therapies.

Latest Patents

Schmitt's latest patents include innovative compounds aimed at treating cancer. One of his notable inventions is related to derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers, which serve as inhibitors of FTL3 and JAK. This invention focuses on a compound that can be utilized as a drug, particularly in cancer treatment, along with the pharmaceutical compositions that contain it and the methods for preparing such compounds. Another significant patent involves isoquinolinone derivatives, which are also aimed at cancer treatment. This invention describes a compound that can be used as a drug, along with its pharmaceutical compositions and preparation processes.

Career Highlights

Throughout his career, Philippe Schmitt has worked with prominent companies in the pharmaceutical industry, including Pierre Fabre Medicament. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Schmitt has collaborated with various professionals in his field, including El Bachir Kaloun and Anna Kruczynski. These collaborations have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Philippe Schmitt is a distinguished inventor whose work in cancer treatment showcases his commitment to advancing medical science. His patents reflect a dedication to developing effective therapies that could benefit many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…